Introduction
Human thyroid tumors constitute several different histopathological and biological subtypes, among which the majority of clinically important cancers are of the follicular and papillary types (Gimm, 2001) . Despite the presumed common cellular origin of follicular and papillary carcinomas, accumulating evidence indicates that follicular thyroid carcinomas (FTCs) arise through an oncogenic pathway distinct from that of papillary thyroid carcinomas (PTCs). In PTC, oncogenic activation of RET or NTRK1 resulting from chromosomal rearrangements leads to abnormal tyrosine kinase activity (Å man, 1999; Pierotti, 2001; Lui and Dwight, 2003) . This functional aberration has been shown to play a pivotal role in PTC oncogenesis. In addition, activating mutations of BRAF were reported recently in a large proportion of PTCs, which may represent an alternative pathway to oncogenic MAPK activation in PTCs without RET-or NTRK1-activation (Cohen et al., 2003; Kimura et al., 2003; Soares et al., 2003; Frattini et al., 2004) .
The identification of a follicular specific fusion oncogene highlights the importance of chromosomal translocations also in these tumors . The first fusion oncogene identified in FTC involves the PAX8 (paired box 8) and PPARg (peroxisome proliferator-activated receptor gamma) genes, and results from a specific translocation between chromosomes 2 and 3, t(2;3)(q13;p25) . Through this translocation, a fusion transcript is expressed in which the 5 0 region of PAX8 is fused in-frame to exon 1 of PPARg. PAX8 encodes a paired domain transcription factor that is essential for normal thyroid development (Poleev et al., 1992) . PPARg is a member of the nuclear hormone receptor subfamily of transcription factors, which is involved in pathways related to cell proliferation and differentiation in various malignancies, in addition to its important role in adipocyte differentiation and insulin sensitization (Manse´n et al., 1996; Fajas et al., 1997 Fajas et al., , 2001 ; Lefebvre et al., 1998; Mueller et al., 1998 Mueller et al., , 2000 .
PAX8-PPARg rearrangements have been demonstrated in FTCs and follicular adenomas, but not in other types of thyroid tumors or hyperplastic nodules Marques et al., 2002; Nikiforova et al., 2002 Nikiforova et al., , 2003 Cheung et al., 2003; Dwight et al, 2003) . Screening of large tumor series has identified PAX8-PPARg in 29-62% of FTCs and much less frequently in adenomas. Taken together, the findings suggest an important role of PAX8-PPARg in the development of follicular thyroid malignancies. In experimental systems, expression of the PAX8-PPARg fusion was found to suppress wild-type PPARg activities . It has therefore been suggested that PAX8-PPARg has a dominant negative function, and that abrogation of the normal PPARg function may play a critical role in tumorigenesis of FTCs. However, the detailed molecular events by which PAX8-PPARg contributes to tumor development are so far largely unknown.
In approaching these questions, global expression profilings were performed using high-density oligonucleotide arrays to highlight molecular signatures of FTCs with and without a PAX8-PPARg fusion. By coupling with computational and statistical analyses, our data show that FTCs possessing a PAX8-PPARg fusion have a highly uniform and distinct gene expression pattern that clearly distinguishes them from FTCs without this fusion.
Results
In this study, global expression profilings were performed on a series of primary FTCs using the HGU95Av2 GeneChip (Affymetrix). The nine tumors (T1-T9) analyzed represent genetically different types of FTC. Four cases (T1-T4) displayed a PAX8-PPARg fusion, as determined on the chromosomal, RNA and protein levels, while the other five cases (T5-T9) were negative for the fusion .
As a first step in the analysis, we asked whether the transcriptional signatures of the FTCs with and without a PAX8-PPARg fusion were molecularly distinct. The 398 genes identified by variation filtering were subjected to two-way hierarchical clustering among the nine tumors in an unsupervised manner. The clustering algorithm grouped both genes and tumors into clusters based on overall similarity in gene expression pattern without prior knowledge of sample identity. Clustering based on the 398 filtered probe sets revealed great variation in overexpressed and underexpressed genes among the tumors ( Figure 1a) . As is evident from the dendrogram at the top of the cluster pattern, the FTCs clustered into two groups, whereby all PAX8-PPARg( þ ) tumors fell into a distinct cluster, with the T9 being the most closely related PAX8-PPARg(À) FTC.
We also performed multidimensional scaling (MDS) analysis, which represents the relationships among all samples in terms of their position in three-dimensional Euclidean space (Figure 1b ). This analysis arranged the PAX8-PPARg(À) FTCs at the periphery of the box, with the PAX8-PPARg( þ ) FTCs falling in a defined cluster. The findings correspond well with the hierarchical clustering data. Taken together, these results clearly suggest that FTCs harboring a PAX8-PPARg fusion display a distinct expression signature.
Reduced expression of ribosomal protein and translationassociated genes in PAX8-PPARg( þ ) FTCs Elucidating patterns from the expression profile can provide great insight into gene function and regulatory systems. For this purpose, we used the Gaussian clustering model to identify functional distinct groups of genes with similar expression profiles. This model takes into account the fact that different functional groups of genes have different variance (spread) of their expression profiles. From the 398 filtered probe sets, we selected five clusters of genes with similar expression profiles in the nine tumors. All five clusters and their correlation with the nine FTCs are illustrated in Figure  2a , and their visual representation in three-dimensional space is shown in Figure 2b . The details of the genes in each cluster are given in Table S1 .
Strikingly, one of the five clusters correlated well with the genetically distinct tumor groups studied (cluster 3, Figure 2a ). This cluster includes ribosomal protein and translation-associated genes (cluster 3, Table S1 ), for which the expression levels were reduced in the PAX8-PPARg( þ ) FTCs as compared to the PAX8-PPARg(À) FTCs. It is noteworthy that this set of genes was also highlighted by the hierarchical clustering ( Figure 1a ).
Highly ranked genes correlated with the PAX8-PPARg( þ ) and the PAX8-PPARg(À) FTCs distinction Using the signal-to-noise (S2N) statistic and permutation tests, we ranked the genes that correlated with each of the two class distinctions, that is, PAX8-PPARg( þ ) and PAX8-PPARg(À) FTCs. The diagrammatic results for the top 50 genes of each class are illustrated in Figure 3 . Notably, highly ranked genes with increased expression in the PAX8-PPARg( þ ) FTCs are mostly associated with signal transduction (e.g. ADCY9, FYN and TNFRSF10B), cell growth (e.g. CTBP2, TP53I11, FSCN1 and EPAC) and chromatin remodeling (e.g. CHD4, SATB1 and SMARCC1). On the other hand, highly ranked genes with reduced expression in the PAX8-PPARg( þ ) FTCs are preferentially related to protein biosynthesis or metabolism, including RPL17, RPL18A, RPL21, RPS5, EIF3S5, eIF3K, RPS2, EIF5, RPS12, RPL10A, DNAJA1, UBE2E3 and SARS.
To determine if related groups of genes from expression clustering share significant functions, the selected genes were analysed with respect to the ontology annotation in the Gene Ontology (GO) database (Ashburner et al., 2000) . We applied GoSurfer to retrieve GO information of the selected overexpressed and underexpressed genes in the PAX8-PPARg( þ ) FTCs, and Pearson's w 2 tests were performed to evaluate which GO paths were associated with significantly more genes in a particular gene set. Two GO paths were found to be statistically significant (Table 1) . A total of 14 genes were categorized in 'Cell growth and/or maintenance' (GO ID: 8151), which was found to be significantly associated with overexpression in PAX8-PPARg( þ ) FTCs (P ¼ 0.02). Remarkably, these overexpressed genes displayed similar expression profiles and mostly grouped in the same cluster (cluster 1, Table S1 and Figure 2a ). The other significant GO path was the 'Protein biosynthesis' (GO ID: 6412) (Po0.01). A total of 11 ribosomal protein and translation-associated genes were found in this category, all of which showed reduced expression in the PAX8-PPARg( þ ) FTCs. Similarly, this group of genes was also grouped in a defined cluster (cluster 3, Table S1 and Figure 2a ).
Validation using real-time RT-PCR
To obtain an independent verification of the array results, real-time RT-PCR was performed on 11 genes, including four genes selected from the list of highly ranked genes and seven genes outside of this list. Of the highly ranked genes, two were underexpressed in PAX8-PPARg( þ ) FTCs (lipopolysaccharide-induced tumor necrosis factor-alpha (LITAF) and beta-2-microglobulin (B2M)) and two were overexpressed in PAX8-PPARg( þ ) FTCs (peroxisome-proliferator activated receptor gamma (PPARg) and cyclin D1 ( High expression of PPARg and CTBP2 in PAX8-
We further evaluated expression of PPARg and CTBP2 using real-time RT-PCR in a larger series of samples Table S1 FTCs with PAX8-PPARc fusion oncogene W-O Lui et al from follicular thyroid tumors and normal thyroid tissues ( Figure 5 ). We observed a significantly higher expression level of PPARg in the PAX8-PPARg( þ ) FTCs as compared to PAX8-PPARg(À) FTCs (P ¼ 0.0002) and normal thyroids (P ¼ 0.036). Conversely, the PPARg expression was significantly lower in the PAX8-PPARg(À) FTCs than in the normal thyroids (P ¼ 0.0003). Expression of CTBP2 was found to be significantly higher in the PAX8-PPARg( þ ) FTCs than in PAX8-PPARg(À) FTCs (P ¼ 0.028) and normal thyroids (P ¼ 0.032). However, no significant deregulated CTBP2 expression was observed for the PAX8-PPARg(À) FTCs as compared to normal thyroids (P ¼ 0.421).
Discussion
The identification of the PAX8-PPARg fusion oncogene in follicular thyroid tumors provides a new starting point to dissect the molecular genetic events involved in the development of FTC. As PAX8-PPARg is only present in 29-62% of FTCs and in a small proportion of follicular adenomas, it can be anticipated that multiple genetic events could be involved in follicular thyroid tumorigenesis. Alternative genetic alterations could then be affecting the same or different pathways as the PAX8-PPARg fusion oncogene. In this study, the gene expression profiles of FTCs that possess a PAX8-PPARg fusion were remarkedly consistent and differed significantly from those of other FTCs. We therefore suggest that follicular thyroid cancers with a PAX8-PPARg fusion oncogene constitute a distinct biological entity in this tumor group. This concept is supported by comparison of FTCs with and without the PAX8-PPARg fusion using both clustering and MDS approaches. In line with this notion, French et al. (2003) demonstrated that FTCs with a PPARg rearrangement display distinct clinicopathological features. Similarly, Nikiforova et al. (2003) proposed that there are at least two distinct molecular pathways involved in thyroid follicular cancer development: one initiated by RAS point mutation and the other by PAX8-PPARg rearrangement. Here, we demonstrate a distinct expression signature in PAX8-PPARg( þ ) FTCs by global transcription profiling.
The MDS analysis showed that FTCs with a PAX8-PPARg fusion were grouped in a defined cluster, while those tumors without the fusion were notably scattered. Strikingly, one of the PAX8-PPARg(À) tumors (T9) was closer to the PAX8-PPARg( þ ) cluster (also revealed by hierarchical clustering analysis). Although we have excluded the presence of a PAX8-PPARg fusion in this tumor , it revealed an abnormal karyotype with translocations between chromosomes 2 and 10 (Foukakis et al., 2004) . It is likely that this tumor showed partially similar but not identical expression profile as the PAX8-PPARg( þ ) tumors. Therefore, the scattered locations of the PAX8-PPARg(À) FTCs demonstrated by MDS analysis correspond with the In an attempt to identify genes whose expression correlates with the PAX8-PPARg genotype, we investigated the gene list with highly ranked differential T1 T2 T3 T4 T5 T6 T7 T8 T9  1   10   1000   100000   1000000   T3  T4  T5  T8  T9  Relative expression level   0   2   4   6   8   T1 T2 T3 T4 T5 T6 T7 T8 T9  0   1   2   3   4   5   T3  T4  T5  T8 
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PPAR (r=0.97) 10000 100 Figure 4 Confirmation of microarray data by quantitative real-time RT-PCR illustrated for LITAF, B2M, PPARg and CCND1. RT-PCR was performed on all or selected cases based on the availability of RNA. Expression levels are given relative to the expression levels of 18S (reference gene). The comparative correlation coefficient (r) for each gene is given for the two assays. The relative expression levels determined by microarray and RT-PCR are indicated by black and white bars, respectively. Note the logarithmic scale for PPARg expression levels FTCs with PAX8-PPARc fusion oncogene W-O Lui et al expression profiles between the two tumor groups. Notably, highly ranked genes with differential expression in the PAX8-PPARg( þ ) FTCs were mostly associated with signal transduction, cell growth and translation control. Several signal transduction genes, including 10 overexpressed (EPOR, IL1R1, GPR51, ADCY9, TNFRSF10B, FYN, EPAC, DUSP6, ARH-GAP1 and DDR1) and four underexpressed (HINT1, RAP1GA1, CSNK2B and SNTA1), were found. Several genes associated with cell proliferation, such as CTBP2, FSCN1 and CCND1, were also overexpressed in the FTCs possessing the PAX8-PPARg fusion. These findings suggest that fusion positive tumors involve partly distinct pathways as compared to the fusion negative cases. Furthermore, a large number of ribosomal protein and translation-associated genes were concurrently underexpressed in the PAX8-PPARg( þ ) FTCs, including RPL17, RPL18A, RPL21, RPS5, EIF3S5, eIF3K, RPS2, EIF5, RPS12, RPL10A and SARS. This suggests that the regulation of translational control was likely to be interrupted. Translational control is an important process that regulates the levels of protein. In addition to a global translational control that regulates the cell's response to external stimuli such as growth factors, cytokines, stress and viral infections, selective translational control has been demonstrated to affect many genes related to growth and apoptotic processes (Clemens and Bommer, 1999; Dua et al., 2001; Dever, 2002) . Interestingly, two recent studies highlight a high coordinate expression of a large number of ribosomal and translation-associated genes in ovarian tumors and chronic lymphocytic leukemias (CLLs). In the study of Welsh et al. (2001) , it was shown that those rapidly growing tumors cell lines and the most poorly differentiated ovarian tumors were grouped together by hierarchical clustering analysis, and exhibited a relative underexpression of ribosomal genes. Similarly, Du¨rig et al. (2003) noticed that a large number of ribosomal and other translation-associated genes were coordinately overexpressed in CLL patients with more favorable clinical outcome. Several previous studies suggested that FTCs harboring a PAX8-PPARg are likely to be histologically more aggressive compared to those without the rearrangement (French et al., 2003; Nikiforova et al., 2003) . Taken together with our data, these observations raise the possibility that a low expression of ribosomal proteins and translation-associated genes may be correlated with a more aggressive clinical course in some tumor entities. However, the present tumor series studied by microarray is too small to allow analyses of possible clinical correlation.
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It has been reported that RNA expression of PPARg was frequently reduced in several types of nonmedullary thyroid cancer, including FTCs, PTCs and Hu¨rthle cell carcinomas (Aldred et al., 2003) . Conversely, its expression in the tumors with a PPARg rearrangement was significantly increased, at least fourfold as compared to the non-PPARg rearranged tumors (Aldred et al., 2003) . In agreement with previously published data, we also observed a significantly increased expression level of PPARg in the PAX8-PPARg( þ ) FTCs. This was first demonstrated in the microarray analyses using both clustering methods (Table S1 ) and then confirmed in each of the informative tumors by quantitative RT-PCR (r ¼ 0.97; Figure 4 ). As the PAX8-PPARg fusion protein inhibits the transcriptional activities of wild-type PPARg in a dominant negative manner, it is therefore suggested that functional downregulation of PPARg is likely to be critical in both PAX8-PPARg( þ ) and nontranslocation thyroid tumors. It is unclear how the loss of the PPARg gene and/or the dominant negative effect of the PAX8-PPARg fusion are involved in thyroid carcinogenesis. Recently, Ying et al. (2003) showed that a mouse model harboring a mutant thyroid hormone beta receptor (TRbPV) abolished the ligand-mediated transcriptional activity of PPARg, and thus concurrently repressed its downstream direct target gene, LPL. PPARg could act via downstream pathways to inhibit the proliferation of cell growth and to induce apoptosis. The loss of these activities of PPARg results in uncontrolled cell growth. Several studies have shown that PPARg agonists and PPARg overexpression leads to a drastic reduction of cell growth and an increase in apoptotic cell death of PPARg-overexpressing thyroid carcinoma cells (Ohta et al., 2001; Martelli et al., 2002) .
In addition, we also evaluated one of the highly ranked genes, CTBP2, in a larger series of tumors. Interestingly, its expression was significantly higher in the PAX8-PPARg( þ ) FTCs, as compared to both PAX8-PPARg(À) FTCs and normal thyroid. CTBPs have been recognized as corepressor proteins, which mediate repression by associating with several transcription factors involved in WNT, TGFb and RAS signaling, and thus implicating its important roles in development and oncogenesis (Chinnadurai, 2002) . Several studies showed that the t(3;21) fusion product (i.e. AML1-EVI1) found in blast transformation of chronic myeloid leukemia or therapy-related acute myeloid leukemia interacts with CTBP and thus blocks myeloid differentiation (Senyuk et al., 2002; Zutsu et al., 2002) . Similarly, it is tempting to speculate that aberrant recruitment of a corepressor complex to PPARg target genes by the PAX8-PPARg fusion protein might play a central role in follicular thyroid tumorigenesis involving this specific fusion. In summary, the current data may have major implications with regard to delineate molecular pathways underlying the pathogenesis of FTC with PAX8-PPARg fusion. Our data clearly show that FTCs harboring the fusion indeed had distinct gene expression pattern, thus implying the involvement of distinct genetic pathways in follicular thyroid oncogenesis. The findings further support the notion that follicular carcinomas with PAX8-PPARg rearrangement are a distinct biological entity, and also support a model in which different genetic alterations initiate distinct pathways of oncogenesis in thyroid carcinoma subtypes.
Materials and methods
Tissue samples
Tumor tissue samples were obtained from patients treated surgically for primary thyroid tumors at the Karolinska University Hospital, Solna. The tumors were classified histopathologically according to the criteria of the WHO committee (Hedinger et al., 1998) . All tissue specimens were obtained in direct connection to surgery, snap-frozen in liquid nitrogen and stored at À801C until use. From each frozen sample used, a representative section was cut and subjected to histopathological evaluation, to confirm the high percentage of tumor cells (>80%) in the samples. Informed consent was obtained from all patients and the study of the tissue samples was approved by the Ethics Committee of the Karolinska University Hospital, Solna.
T1-T9 were all diagnosed as sporadically occurring primary follicular thyroid carcinomas. Histopathologically, all PAX8-PPARg( þ ) tumors (T1-T4) were classified as minimally invasive FTCs. Four of the PAX8-PPARg(À) tumors (T5-T8) were diagnosed as minimally invasive FTCs, and one as widely invasive FTC (T9). Two patients (T2 and T9) presented with distant metastases at the time of surgery. The patients were followed up for 3-10 years, during which time no recurrence of the disease occurred.
In the real-time RT-PCR, additional 17 PAX8-PPARg(À) FTCs and one PAX8-PPARg( þ ) atypical follicular thyroid adenoma were also included. In addition, histopathologically verified normal thyroid tissues were obtained from the contralateral lobe of six patients as controls.
Assessment of the presence of a PAX8-PPARg fusion
All tumor samples were previously screened for the presence of a PAX8-PPARg fusion . The analyses included (1) an interphase FISH fusion assay with BAC RP11-368K23 (telomeric to PAX8 in 2q14) and BAC RP11-57D6 (centromeric to PPARg in 3p25); (2) RT-PCR and sequencing and (3) Western analyses with PAX8 and PPARg antibodies.
RNA isolation
Total RNA was isolated from all tumors and normal thyroid tissues using the TRIzol Reagent (GIBCO BRL). After purification with the RNeasy kit (Qiagen), the OD 260/280 (interval 1.9-2.1) of the RNA was determined by spectrophotometry. The integrity of the RNA was confirmed by the demonstration of sharp 28S and 18S bands at electrophoresis in denaturing agarose gels. For T1-T9 used in the array hybridizations, the RNA quality was also confirmed by analysis in an Agilent 2100 Bioanalyser (Agilent Technologies Inc., Palo Alto, CA, USA).
Microarray analysis
For each of the nine tumors (T1-T9), cDNA was synthesized from total RNA using a T7-linked oligo-dT primer, and used for cRNA synthesis with biotinylated-UTP and CTP. After fragmenting, the labeled RNAs were hybridized to HGU95Av2 oligonucleotide arrays (Affymetrix Incorporated, Santa Clara, CA, USA) according to the protocol recommended by the supplier. The arrays were then washed and stained with streptavidin-phycoerythrin (Molecular Probes Inc., Eugene, OR, USA) in an Affymetrix fluidics station. Scanning of the arrays was performed on an Affymetrix scanner and the expression values for each gene probe set were calculated using the Affymetrix GeneChip software. Scan quality was assured based on a priori quality control criteria, including the absence of visible microarray artifacts and significant differences in microarray intensity, and a minimum of 1000 probe sets receiving 'Present' calls. To minimize discrepancies resulting from individual variations in sample preparation, local hybridization condition, staining or probe array lot, all probe sets were scaled from each array to a target intensity value of 100, thus allowing interarray comparisons.
Data preprocessing
Gene expression values were subjected to a variation filter that excluded genes showing minimal variation across the samples. Thereby, genes were excluded if the expression levels were less than three-fold and 100 units absolute variation across the data set after a threshold of 100 and 16 000 units was applied. After data filtering, 398 probe sets remained for clustering and statistical analyses.
Hierarchical clustering
The data set was median-polished (i.e. all row-wise and column-wise median values were adjusted close to zero) and normalized (i.e. all row and column magnitudes were adjusted close to 1.0). Average-linkage hierarchical clustering was performed using the CLUSTER and TREEVIEW softwares (Eisen et al., 1998) .
Multidimensional scaling
MDS was used to visualize the similarity of gene expression profiles among the tumor samples. The similarity of the gene expression profiles was assessed by Euclidean distance for the 398 probe sets using the XLSTAT-Pro 7.0 and visualized by the XLSTAT-3DPlot softwares (Addinsoft, http:// www.xlstat.com/). The MDS plot shows sample positions in a three-dimensional space. Samples with similar expression profiles are placed near each other in the MDS plot and separated from other more dissimilar groups.
Gaussian clustering
Gaussian clustering model was applied to identify distinct functional groups of genes with similar expression profiles in the tumors. This model takes into account the fact that different functional groups of genes have different variance (spread) of their expression profiles. Using Pearson's coefficient as the distance metric, the expression profiles for the 398-filtered probe sets were grouped into five clusters in ArrayMiner 5.1 (Optimal Design Belgium, http://www.optimaldesign.com/ArrayMiner/ArrayMiner.htm).
Neighborhood analysis
For marker gene selection, we used the S2N statistic to rank the genes that correlated with the PAX8-PPARg( þ ) and the PAX8-PPARg(À) distinction using the GeneCluster 2 (Golub et al., 1999) . In the S2N statistics, the mean (m) and standard deviation (s) of expression for each class were calculated according to the formula (m 0 Àm 1) /(s 0 þ s 1 ). In addition, the significance of the highly ranked genes was confirmed by random permutation testing; the sample classification labels were permuted, and the S2N ratio was recomputed to compare the true gene correlations to what would have been expected by chance. To do this, we identified the genes that correlated with the class distinction using the S2N statistic and then compared these differences to differences found when the samples were randomly assigned to a class. A total of 1000 permutations of the data were used to identify the top 50 genes of each class distinction.
The top 50 genes of each class distinction were then selected for GO annotation using the GoSurfer program (http:// www.biostat.harvard.edu/complab/gosurfer/). GoSurfer allows comparisons among different sets of genes, such as the selected overexpressed and underexpressed genes in the PAX8-PPARg( þ ) FTCs in this study. These genes were mapped onto Gene Ontology tree, and Pearson's w 2 tests were performed to determine which GO paths were associated with significantly more genes in a particular gene set.
Quantitative real-time RT-PCR analyses
The mRNA expression levels of LITAF, B2M, CCND1, PPARg, CTBP2, CAV1, EGR2, FMOD, JUN, PRKCD, ATP6V1A1, STAT3 and an endogenous housekeeping gene encoding for 18S ribosomal RNA as a reference were quantified using TaqMan technology on an ABI PRISM 7700 sequence detection systems (PE Applied Biosystems). Sequence-specific primers and probes were selected from the Assay-on-Demand products (Applied Biosystems), including LITAF (assay ID: Hs00191583_m1), B2M (Hs00187842_m1), CCND1 (Hs00277039_m1), PPARg (Hs00234592_m1), CTBP2 (Hs00256072_m1), CAV1 (Hs00184697_m1), EGR2 (Hs00166165_m1), FMOD (Hs00157619_m1), JUN (Hs00277190_s1), PRKCD (Hs00178914_m1), ATP6V1A (Hs00156003_m1), STAT3 (Hs00234174_m1) and 18S ribosomal RNA (Hs99999901_s1). All gene expression assays had an FAM reporter dye at the 5 0 end of the TaqMan MGB probe, and a nonfluorescent quencher at the 3 0 end of the probe.
cDNA of each sample was synthesized from 1 mg of RNA pretreated with DNase I (Qiagen) using MultiScribe reverse transcriptase primed with random hexamers (high-capacity cDNA archive kit; Applied Biosystems). The quantitative realtime RT-PCR was performed in a total reaction volume of 25 ml containing 1 Â TaqMan Universal Master Mix, 1 Â Target Assay Mix (Applied Biosystems) and 10 ml of cDNA from each sample as a template, in MicroAmp optical 96-well plates covered with MicroAmp optical caps (Applied Biosystems). Samples were heated for 2 min at 501C and amplified for 40 cycles of 15 s at 951C and 1 min at 601C. cDNA derived from an EBV-transformed normal lymphoblastoid cell line was serially diluted in dH 2 O and amplified in parallel as a control of amplification efficiency within each experiment, and to establish a standard curve for relative quantitation. For each sample, the amount of target mRNA was normalized to the standard curve and then normalized to 18S ribosomal RNA expression. All quantitative real-time RT-PCR experiments included a no template control and were performed in duplicate. The correlation coefficient (r) and unpaired t-test for each gene were calculated using the statistic tool in Microsoft Excel.
